TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05357534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity: 10 km run on a treadmill

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity: 10 km run on a treadmill
Study: NCT05028764

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swabs, Blood Draws and Skin Punch Biopsy
Description: Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swabs, Blood Draws and Skin Punch Biopsy
Description: Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
Study: NCT05260177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy System (LTS): Active Setting
Description: Exposure for 1 hour á day for consecutive days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Light Therapy System (LTS): Sham Setting
Description: Exposure for 1 hour á day for consecutive days
Study: NCT05532215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: The misoprostol tablets to be used in the study will be of the same brand and batch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The oxytocin ampoules to be used in the study will be of the same brand and batch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: The oxytocin ampoules to be used in the study will be of the same brand and batch
Study: NCT06223295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focal therapy
Description: Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
Study: NCT06070090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The traditional East Asian methods of treating disease by inserting needles along specific pathways or meridians.
Study: NCT05254080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active taVNS
Description: Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active taVNS
Description: Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham taVNS
Description: Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.
Study: NCT05920499

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUDIT and Feedback
Description: AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AUDIT and Feedback
Description: AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group.
Study: NCT04607902

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy SSI
Description: Online, 30-minute self-administered program for youth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation SSI
Description: Online, 30-minute self-administered program for youth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset SSI
Description: Online, 30-minute self-administered program for youth
Study: NCT05304845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: acetylsalicylic acid
Study: NCT05488951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
Study: NCT04739033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VIVIR MEJOR EXPERIMENTAL
Description: This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIVIR MEJOR EXPERIMENTAL
Description: This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
Study: NCT04777760

Intervention type: DRUG
Intervention: one dose of surfactant replacement
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant

Intervention type: DRUG
Intervention: two and more doses of surfactant replacement
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Study: NCT05923918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_M2101 2-Day
Description: Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_M2101 1-Day
Description: Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sulfate Tablet 2-Day
Description: Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
Study: NCT05867758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial group intervention
Description: The psychosocial group intervention is composed of 8 weekly sessions of 90 minutes each and the receiving of self-help digital materials. Both organized as following: 2 on isolation, loneliness and social connection, 2 on well-being, 2 on the use of digital tools, 2 on the fostering of socialization with peers.~To evaluate the effects of the blended intervention and of the two conditions we will ask participants to fulfill the following clinical questionnaires: ULS-6 (Russell et al. 1980), MSPSS (Zimet et al., 1988), GAD-7 (Spitzer et al., 2006), PHQ-9 (Kroenke, Spitzer \& Williams, 2001), SWLS (Diener et al., 1985), MLQ (Steger et al., 2006) before starting the intervention in presence and online (T0), at the end of that period (T1) and 2 months after (T2).
Study: NCT05657366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage
Description: Continuous abdominal flushing with normal saline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage
Description: Continuous abdominal flushing with normal saline
Study: NCT04733586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided fascia iliaca
Description: Sonar guided fascia iliaca

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided quadratus lumborum block
Description: Sonar guided quadratus lumborum block
Study: NCT06145503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dance Intervention Group
Description: The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
Study: NCT05053269

Intervention type: OTHER
Intervention: good body weight growth
Description: body weight growth after birth is consistent with the growth curve

Intervention type: OTHER
Intervention: poor body weight growth
Description: body weight growth after birth is inconsistent with the growth curve
Study: NCT05091983

Intervention type: OTHER
Intervention: Sensory Processing Scale Inventory (SPSI)
Description: The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire

Intervention type: OTHER
Intervention: Sensory Processing Scale Inventory (SPSI)
Description: The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire

Intervention type: OTHER
Intervention: Autism Spectrum Screening Quotient (ASSQ)
Description: The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents.

Intervention type: OTHER
Intervention: Autism Spectrum Screening Quotient (ASSQ)
Description: The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents.

Intervention type: OTHER
Intervention: GAD 7
Description: The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire.

Intervention type: OTHER
Intervention: GAD 7
Description: The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire.

Intervention type: OTHER
Intervention: Conners abridged
Description: The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents.

Intervention type: OTHER
Intervention: Conners abridged
Description: The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents.

Intervention type: OTHER
Intervention: EAT 26
Description: The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire.
Study: NCT06415019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen (BAYH006689)
Description: BAYH006689 gel will be dispensed directly on the patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo gel will be dispensed directly on the patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A solution of 0.9% Saline
Description: 0.9% Saline will be dispensed directly on the patch.
Study: NCT05460299

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Telko plus conventional physical therapy (CPT)
Description: All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telko plus conventional physical therapy (CPT)
Description: All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
Study: NCT04609683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AleriTM sensors
Description: AleriTM sensors are worn on the bicep or forearm and communicates through BLETM to a mobile App. The data is sent through the mobile App to web-based system processing where PHI is calculated and sent back to the mobile App.~The AleriTM sensor has a form factor similar to a conventional arm band, with a hockey puck shape of approximately 48mm in diameter and 15mm in thickness the AleriTM sensor is a non-significant risk (NSR) device as it does not meet the definition of significant risk device (21 CFR 812.3(m)) because it is: not an implant; is not purported or represented to support or sustain human life; its use is not of substantial importance in the diagnosis, cure, treatment, mitigation, or prevention of impairment of health; and it does not present a serious risk to the health, safety, or welfare of a subject.
Study: NCT05923047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Patients in the Mepolizumab arms will receive 100 mg of subcutaneous mepolizumab every 4 weeks for a total of 12 doses in addition to daily topical corticosteroid treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypeptomy
Description: This group will undergone in-office nasal polypectomy.
Study: NCT05537311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Engagement
Description: 30-45 minutes of social engagement provided to patients in ICU. Social engagement strategies including meaningful conversation, cognitive stimulation, and emotional support
Study: NCT05582278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-TACE
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 100 mg/m2 infusion for 2 hours; calcium levofolinate, 200 mg/m2 infusion for 1 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: tislelizumab 200 mg, every 3 weeks.
Study: NCT06354218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab （4.5mg/Kg every 3 weeks）
Study: NCT05627518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaprazan glurate
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: 100 mg
Study: NCT05185466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Supported Self Management Programme
Description: Training and incentives to improve nutrition habits and sleep health.
Study: NCT05911477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhBMP-2
Description: 1mg RhBMP-2 for one fusion-level
Study: NCT04823312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prospective single arm evaluating the Medtronic Duo Extended Set
Description: Subjects will be using 4 Duo extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
Study: NCT05775627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Participants are randomized into either a group (n=10) that is sleep restricted first or control first (n=10) group; the groups will crossover halfway through the protocol. Both arms are fed 3 meals and have access to ad libitum food between meals. Both groups will also undergo up to 3 mixed-meal tolerance tests to measure glucose tolerance.
Study: NCT04951089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel Supraglottic device insertion
Description: i-gel insertion for oxygenation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q SP 3G Supraglottic device insertion
Description: Air-Q SP 3G insertion for oxygenation
Study: NCT06298955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS906 study drug
Description: OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
Study: NCT00105742

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diagnosis